

ELENCO LAVORI IN EXTENSO SU RIVISTE CENSITE SU PUBMED, SCOPUS O WEB OF SCIENCE

1. **Filippi L**, Urso L, Ferrari C, Guglielmo P, Evangelista L. (2024). The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN: 1619-7070, doi: 10.1007/s00259-024-06866-9
2. Proietti, Ilaria, **Luca Filippi**, Oreste Bagni, and Concetta Potenza. 2024. "Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study" Journal of Clinical Medicine 13, no. 17: 5087. <https://doi.org/10.3390/jcm13175087>
3. Boschi A, Urso L, Uccelli L, Martini P, **Filippi L** (2024). 99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications.. EJNMMI RADIOPHARMACY AND CHEMISTRY, ISSN: 2365-421X, doi: 10.1186/s41181-024-00264-0
4. **Filippi L**, Urso L, Ferrari C, et al. (2024). Extramedullary disease in multiple myeloma: what you might not expect on [18F]FDG PET/CT - a pictorial essay. CLINICAL AND TRANSLATIONAL IMAGING, ISSN: 2281-5872, doi: 10.1007/s40336-024-00648-x
5. **Filippi L**, Camedda R, Frantellizzi V, Urbano N, De Vincentis G, Schillaci O. (2024). Functional Imaging in Musculoskeletal Disorders in Menopause.. SEMINARS IN NUCLEAR MEDICINE, ISSN: 0001-2998, doi: doi: 10.1053/j.semnuclmed.2023
6. De Rimini, M.L., Bianchi, A., Annovazzi, A., **Filippi L**, Evangelista, L. (2024). Lymphoid organs' metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study. CLINICAL AND TRANSLATIONAL IMAGING, ISSN: 2281-7565, doi: 10.1007/s40336-023-00614-z
7. **Filippi L**, Brechbiel MW. (2024). Molecular Breast Imaging of HER2-Positive Breast Cancer in the Era of PHERGain Trial: The past, the Present, and the Prospects.. CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, ISSN: 1084-9785, doi: 10.1089/cbr.2024.0081
8. **Filippi L**, Schillaci O. (2024). NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?. EXPERT REVIEW OF ANTICANCER THERAPY, ISSN: 1473-7140, doi: 10.1080/14737140.2023.2288140
9. **Filippi L**, Lacanfora A, Garaci F. (2024). One Fell Swoop: Septic Muscle Embolism and Central Venous Catheter Infection Imaged with [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. DIAGNOSTICS, ISSN: 2075-4418, doi: 10.3390/diagnostics14020180
10. **Filippi L**, Urso L, Evangelista L. (2024). PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.. CURRENT ISSUES IN MOLECULAR BIOLOGY, ISSN: 1467-3037, doi: 10.3390/cimb46040190
11. Urso L, **Filippi L** (2024). Phosphorus-32 microparticles for locally advanced pancreatic cancer: how and when?. EXPERT REVIEW OF MEDICAL DEVICES, ISSN: 1743-4440, doi: 10.1080/17434440.2024.2352009
12. Camedda R, Frantellizzi V, Danieli R, De Vincentis G, **Filippi L** (2024). Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review.. EXPERT REVIEW OF ANTICANCER THERAPY, ISSN: 1473-7140, doi: 10.1080/14737140.2024.2328167
13. **Filippi L**, Evangelista L. (2024). Something still missing in molecular imaging: CXCR2 axis in prostate cancer. . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN: 1619-7070, doi: 10.1007/s00259-023-06501-z
14. **Filippi L**, Proietti I, Petrozza V, Potenza C, Bagni O, Schillaci O. (2024). The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study.. CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, ISSN: 1084-9785, doi: 10.1089/cbr.2023.0110
15. Bianconi F, Salis R, Fravolini ML, Khan MU, Minestrini M, **Filippi L**, Marongiu A, Nuvoli S, Spanu A, Palumbo B.

- Performance Analysis of Six Semi-Automated Tumour Delineation Methods on [¹⁸F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in Patients with Head and Neck Cancer. *Sensors (Basel)*. 2023 Sep 18;23(18):7952. *Impact factor (IF): 3.9*
16. D'Arienzo M, Mezzenga E, Capotosti A, Bagni O, **Filippi L**, Capogni M, Indovina L, Sarnelli A. The Importance of Uncertainty Analysis and Traceable Measurements in Routine Quantitative ⁹⁰Y-PET Molecular Radiotherapy: A Multicenter Experience. *Pharmaceuticals (Basel)*. 2023 Aug 11;16(8):1142. *IF: 4.6*
 17. Conte M, De Feo MS, Frantellizzi V, Tomaciello M, Marampon F, Evangelista L, **Filippi L**, De Vincentis G. Radio-Guided Lung Surgery: A Feasible Approach for a Cancer Precision Medicine. *Diagnostics (Basel)*. 2023 Aug 9;13(16):2628. doi: 10.3390/diagnostics13162628 *IF: 3.6*
 18. **Filippi L**, Frantellizzi V, De Vincentis G, Schillaci O. The new bone WB-SPECT/CT: hybrid, from head-to-toe and digital! Is it worth the effort? *Expert Rev Med Devices*. 2023 Jul-Dec;20(10):791-795. *IF: 3.1*
 19. **Filippi L**, Urso L, Schillaci O, Evangelista L. [¹⁸F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review. *Diagnostics (Basel)*. 2023 Aug 7;13(15):2613. *IF: 3.6*
 20. Conte M, De Feo MS, Frantellizzi V, Marampon F, **Filippi L**, Schillaci O, De Vincentis G. Extrasosseous distribution of ^{99m}Tc-diphosphonates during bone scintigraphy: review of the literature with case series presentation. *Int J Radiat Biol*. 2023 Aug 10:1-10. *IF: 2.6*
 21. **Filippi L**, Schillaci O. Something old has become new: PET imaging of neural-crest tumors with [¹⁸F]-meta-fluorobenzylguanidine. *Clin Transl Imaging* 11, 235–240 (2023). *IF: 2.1*
 22. De Feo, M.S., **Filippi L**, Frantellizzi, V. *et al*. Multiple myeloma: characterization of patients through the analysis of semiquantitative parameters with 18F-FDG PET. *Egypt J Radiol Nucl Med* 54, 114 (2023). *IF: 1*
 23. **Filippi L**, Evangelista L, Schillaci O. [¹⁸F]Fluoropivalate, mitochondria, and the resurrection of short-chain fatty acids. *Eur J Nucl Med Mol Imaging*. 2023 Jul 31. doi: 10.1007/s00259-023-06367-1. *IF: 9.1*
 24. **Filippi L**, Frantellizzi V, Bartoletti P, Vincentis G, Schillaci O, Evangelista L. Head-to-Head Comparison between FDG and 11C-Methionine in Multiple Myeloma: A Systematic Review. *Diagnostics (Basel)*. 2023 Jun 9;13(12):2009 *IF: 3.6*
 25. Evangelista L, Fiz F, Laudicella R, Bianconi F, Castello A, Guglielmo P, Liberini V, Manco L, Frantellizzi V, Giordano A, Urso L, Panareo S, Palumbo B, **Filippi L**. PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature. *Cancers (Basel)*. 2023 Jun 20;15(12):3258. *IF: 5.2*
 26. Evangelista L, **Filippi L**, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. *Ann Nucl Med*. 2023 Aug;37(8):442-450. *IF: 2,6*
 27. Gorica J, De Feo MS, Corica F, Sidrak MMA, Conte M, **Filippi L**, Schillaci O, De Vincentis G, Frantellizzi V. Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Perspectives: A Systematic Review. *Pharmaceuticals (Basel)*. 2023 Feb 17;16(2):313. *IF: 5.4*
 28. **Filippi L**, Urso L, Schillaci O, Evangelista L. Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? *Semin Nucl Med*. 2023 Jun 1:S0001-2998(23)00038-7. *IF: 4,6*
 29. **Filippi L**, Frantellizzi V, Vincentis G, Schillaci O, Evangelista L. Clinical Applications of TSPO PET for Glioma Imaging: Current Evidence and Future Perspective-A Systematic Review. *Diagnostics (Basel)*. 2023 May 21;13(10):1813. *IF: 3,6*
 30. Conte M, De Feo MS, Sidrak MMA, Corica F, Gorica J, Granese GM, **Filippi L**, De Vincentis G, Frantellizzi V. Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook. *Diagnostics (Basel)*. 2023 May 9;13(10):1682. *IF: 3,6*
 31. **Filippi L**, Evangelista L, Schillaci O. Integrated use of ⁹⁰Y-labeled microspheres and immune checkpoint inhibitors in hepatic tumors: current status and future directions. *Expert Rev Gastroenterol Hepatol*. 2023 Jan-Jun;17(6):531-538. *IF: 3.9*

32. **Filippi L**, Chiaravalloti A. Prostate Cancer: From Molecular Imaging to Immunological and Target Therapies. *Biomedicines*. 2023 Apr 14;11(4):1176. *IF*: 4.7
33. De Feo MS, Frantellizzi V, Bauckneht M, Farcomeni A, **Filippi L**, Rizzini EL, Lavelli V, Stazza ML, Di Raimondo T, Fornarini G, Rebuzzi SE, Filippo M, Mammucci P, Marongiu A, Monari F, Rubini G, Spanu A, De Vincentis G. The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl₂: A Multicenter Italian Study. *Biomedicines*. 2023 Apr 5;11(4):1103. *IF*: 4.7
34. Conte M, De Feo MS, Corica F, Gorica J, Sidrak MMA, De Cristofaro F, **Filippi L**, Ricci M, De Vincentis G, Frantellizzi V. A Systematic Review on Dementia and Translocator Protein (TSPO): When Nuclear Medicine Highlights an Underlying Expression. *Biomolecules*. 2023 Mar 26;13(4):598. *IF*: 5.5
35. Evangelista L, Frantellizzi V, Schillaci O, **Filippi L**. Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients? *Expert Rev Anticancer Ther*. 2023 Jul;23(7):745-752. *IF*: 3.3
36. Sidrak MMA, De Feo MS, Corica F, Gorica J, Conte M, **Filippi L**, Evangelista L, De Vincentis G, Frantellizzi V. Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review. *Life (Basel)*. 2023 Apr 11;13(4):989. *IF*: 3.2
37. Nyakale N, **Filippi L**, Aldous C, Satheke M. Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma. *Cancers (Basel)*. 2023 Mar 25;15(7):1975. *IF*: 5.2
38. Conte M, De Feo MS, Sidrak MMA, Corica F, Gorica J, **Filippi L**, Schillaci O, De Vincentis G, Frantellizzi V. Radiolabeled Dendrimer Coated Nanoparticles for Radionuclide Imaging and Therapy: A Systematic Review. *Pharmaceutics*. 2023 Mar 7;15(3):867. *IF*: 5.4
39. Corica F, De Feo MS, Gorica J, Sidrak MMA, Conte M, **Filippi L**, Schillaci O, De Vincentis G, Frantellizzi V. PET Imaging of Neuro-Inflammation with Tracers Targeting the Translocator Protein (TSPO), a Systematic Review: From Bench to Bedside. *Diagnostics (Basel)*. 2023 Mar 8;13(6):1029. *IF*: 3.6
40. Sidrak MMA, De Feo MS, Corica F, Gorica J, Conte M, **Filippi L**, Schillaci O, De Vincentis G, Frantellizzi V. Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review. *Int J Mol Sci*. 2023 Feb 15;24(4):3863. *IF*: 5.6
41. **Filippi L**, Urso L, Bianconi F, Palumbo B, Marzola MC, Evangelista L, Schillaci O. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. *Expert Rev Mol Diagn*. 2023 Mar;23(3):243-255. *IF*: 5.1
42. **Filippi L**. Incidental Detection of Pseudomembranous Colitis Through ¹⁸F-FDG PET/CT During the Restaging of Colorectal Cancer. *Mol Imaging Radionucl Ther*. 2023 Feb 23;32(1):71-73. doi: 10.4274/mirt.galenos.2022.94547. *IF*: 0.9
43. **Filippi L**, Brechbiel MW. Immunotherapy for Cancer: Something Old, Something New. *Cancer Biother Radiopharm*. 2023 May;38(4):209-210. *IF*: 3.4
44. Chiaravalloti A, **Filippi L**, Pagani M, Schillaci O. Functional imaging of chemo-brain: usefulness of Nuclear Medicine in the fog coming after cancer. *J Nucl Med*. 2023 Feb 2;jnumed.121.263294. doi: 10.2967/jnumed.121.263294. *IF*: 9.3
45. Lopci E, Castello A, **Filippi L**. Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy. *Cancer Biother Radiopharm*. 2023 Feb 2. doi: 10.1089/cbr.2022.0091. *IF*: 3.4
46. **Filippi L**, Proietti I, Petrozza V, Aversa S, Fiorentino F, Potenza C, Bagni O, Schillaci O, Cantonetti M. [18F]FDG PET/CT in a Case of Mycosis Fungoides Showing an Unusual Adverse Reaction to Mogamulizumab: Correlation Between Imaging and Histological Findings. *Cancer Biother Radiopharm*. 2023 Jan 27. doi: 10.1089/cbr.2022.0086. *IF*: 3.4
47. **Filippi L**. COVID-19 lessons learned: medical devices at the core of global healthcare. A foreword on new challenges for expert review of medical devices! *Expert Rev Med Devices*. 2023 Jan;20(1):1-3. doi:

10.1080/17434440.2023.2171863. *IF*: 3.1

48. **Filippi L**, Palumbo B, Bagni O, Frantellizzi V, De Vincentis G, Schillaci O. DNA Damage Repair Defects and Targeted Radionuclide Therapies for Prostate Cancer: Does Mutation Really Matter? A Systematic Review. *Life (Basel)*. 2022 Dec 24;13(1):55. doi: 10.3390/life13010055. *IF*: 3.2
49. Sidrak MMA, De Feo MS, Frantellizzi V, Marongiu A, Caponnetto S, **Filippi L**, Nuvoli S, Spanu A, Schillaci O, De Vincentis G. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review. *Cancer Biother Radiopharm*. 2023 Jan 9. doi: 10.1089/cbr.2022.0049. *IF*: 3.4
50. **Filippi L**, Bagni O, Notarianni E, Saltarelli A, Ambrogi C, Schillaci O. PET/CT with 18F-choline or 18F-FDG in Hepatocellular Carcinoma Submitted to 90Y-TARE: A Real-World Study. *Biomedicines*. 2022 Nov 21;10(11):2996. doi: 10.3390/biomedicines10112996. *IF*: 4.7
51. **Filippi L**, Palumbo B, Frantellizzi V, Nuvoli S, De Vincentis G, Spanu A, Schillaci O. Prostate-specific membrane antigen-directed imaging and radioguided surgery with single-photon emission computed tomography: state of the art and future outlook. *Expert Rev Med Devices*. 2022 Nov;19(11):815-824. doi: 10.1080/17434440.2022.2146999. *IF*: 3.1
52. Gorica J, De Feo MS, **Filippi L**, Frantellizzi V, Schillaci O, De Vincentis G. Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives. *Expert Rev Mol Diagn*. 2022 Nov;22(11):991-996. doi: 10.1080/14737159.2022.2145187. *IF*: 5.1
53. **Filippi L**, Urso L, Schillaci O, Evangelista L. Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? *Semin Nucl Med*. 2023 Jun 1:S0001-2998(23)00038-7. doi: 10.1053/j.semnuclmed.2023.05.002. *IF*: 4.9
54. Poletto G, Cecchin D, Sperti S, **Filippi L**, Realdon N, Evangelista L. Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review. *Curr Issues Mol Biol*. 2022 Nov 7;44(11):5516-5530. doi: 10.3390/cimb44110373. *IF*: 3.1
55. **Filippi L**, Dimitrakopoulou-Strauss A, Evangelista L, Schillaci O. Long axial field-of-view PET/CT devices: are we ready for the technological revolution? *Expert Rev Med Devices*. 2022 Oct;19(10):739-743. doi: 10.1080/17434440.2022.2141111. *IF*: 3.1
56. Nuvoli S, Bianconi F, Rondini M, Lazzarato A, Marongiu A, Fravolini ML, Cascianelli S, Amici S, **Filippi L**, Spanu A, Palumbo B. Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypometabolism on 18F-FDG PET/CT and Automated Classifiers. *Diagnostics (Basel)*. 2022 Oct 7;12(10):2425. doi: 10.3390/diagnostics12102425. *IF*: 3.6
57. **Filippi L**, Bagni O, Schillaci O. Digital PET/CT with 18F-FACBC in early castration-resistant prostate cancer: our preliminary results. *Expert Rev Med Devices*. 2022 Aug 24. doi: 10.1080/17434440.2022.2117612. *IF*: 3.1
58. **Filippi L**, Evangelista L, Sathekge MM et al. ImmunoPET for prostate cancer in the PSMA era: do we need other targets?. *Clin Transl Imaging* (2022). <https://doi.org/10.1007/s40336-022-00520-w>. *IF*: 2.1
59. **Filippi L**, Braat AJ, Schillaci O. The era of prostate-specific membrane antigen (PSMA)-based theranostics for hepatocellular carcinoma is upcoming: are we ready for it? *Eur J Nucl Med Mol Imaging*. 2022 Aug 10. doi: 10.1007/s00259-022-05928-0. *IF*: 1.3
60. **Filippi L**, Palumbo I, Bagni O, Schillaci O, Aristei C, Palumbo B. Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature. *Diagnostics (Basel)*. 2022 Jul 8;12(7):1666. doi: 10.3390/diagnostics12071666. *IF*: 3.6
61. **Filippi L**, Spanu A., Bagni O et al. Imaging Findings of 18F-Choline and 18F-DOPA PET/MRI in a Case of Glioblastoma Multiforme Pseudoprogression: Correlation with Clinical Outcome. *Nucl Med Mol Imaging* (2022). <https://doi.org/10.1007/s13139-022-00758-2> *IF*: 1.3

62. Marcellino A, Bloise S, Fraternali R, Pirone C, Brandino G, Testa A, **Filippi L**, Lubrano R. Evaluation of renal function and scars in children with primary vesicoureteral reflux. *Urology*. 2022 Jun 30:S0090-4295(22)00530-1. doi: 10.1016/j.urology.2022.06.020. *IF*: 2.1
63. **Filippi L**, Bianconi F, Schillaci O, Spanu A, Palumbo B. The Role and Potential of 18F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics. *Diagnostics (Basel)*. 2022 Apr 8;12(4):929. doi: 10.3390/diagnostics12040929. *IF*: 3.6
64. **Filippi L**, Bagni O, Schillaci O. Multimodality radionuclide imaging in fever of unknown origin presenting with a solitary spleen lesion. *Egypt J Radiol Nucl Med* 53, 109 (2022). <https://doi.org/10.1186/s43055-022-00788-y> *IF*: 1
65. **Filippi L**, Schillaci O. Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true? *Eur J Nucl Med Mol Imaging*. 2022 Apr 9. doi: 10.1007/s00259-022-05791-z. *IF*: 9.1
66. **Filippi L**, Proietti I, Petrozza V, Bagni O, Schillaci O. Cutaneous Squamous Cell Carcinoma Subjected to Anti PD-1 Immunotherapy: Monitoring Response Through Serial PET/CT Scans with 18F-FDG. *Cancer Biother Radiopharm*. 2022 Apr;37(3):226-232. doi: 10.1089/cbr.2021.0368. *IF*: 3.4
67. **Filippi L**, Bagni O, Crisafulli C, Cerio I, Brunotti G, Chiaravalloti A, Schillaci O, Dore F. Detection Rate and Clinical Impact of PET/CT with 18F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study. *Biomedicines*. 2022 Jan 15;10(1):177. doi: 10.3390/biomedicines10010177. *IF*: 4.7
68. **Filippi L**, Schillaci O, Palumbo B. Neuroimaging with PET/CT in chronic traumatic encephalopathy: what nuclear medicine can do to move the field forward. *Expert Rev Mol Diagn*. 2022 Feb 2:1-8. doi: 10.1080/14737159.2022.2035723. *IF*: 5.1
69. **Filippi L**, Braat AJ. Theranostics in primary and secondary liver tumors: the need for a personalized approach. *Q J Nucl Med Mol Imaging*. 2021 Dec 9. doi: 10.23736/S1824-4785.21.03407-5. *IF*: 1.5
70. **Filippi L**, Schillaci O. Digital PET and detection of recurrent prostate cancer: what have we gained, and what is still missing? *Expert Rev Med Devices*. 2021 Nov;18(11):1107-1110. doi: 10.1080/17434440.2021.1990036. *IF*: 3.1
71. **Filippi L**, Proietti I, Schillaci O, Potenza C, Bagni O. A rare case of pancreatic metastasis from malignant melanoma mimicking pancreatitis on 18F-FDG PET/CT. *J Egypt Natl Canc Inst*. 2021 Oct 11;33(1):29. doi: 10.1186/s43046-021-00087-z. *IF*: 1.8
72. **Filippi L**, Frantellizzi V, De Vincentis G. David versus Goliath: Radiotheranostic nanomedicine as a weapon against melanoma. *Cancer Treat Res Commun*. 2021 Oct 17;29:100478. doi: 10.1016/j.ctarc.2021.100478.
73. Chiaravalloti A, Ricci M, Cimini A, Russo F, Ursini F, **Filippi L**, Schillaci O. 18F-FDOPA PET/CT SUV-Derived Indices and Volumetric Parameters Correlation in Patients with Primary Brain Tumors. *Cancers (Basel)*. 2021 Aug 26;13(17):4315. doi: 10.3390/cancers13174315. *IF*: 5.2
74. **Filippi L**, Frantellizzi V, Monari F, Lodi Rizzini E, Tabacchi E, Pirisino R, Marongiu A, Nuvoli S, Bagni O, De Vincentis G, Schillaci O, Spanu A. Usefulness of PET/CT with 18F-FDG in Patients with Differentiated Thyroid Carcinoma after Radioiodine Therapy: An Italian Multicenter Study. *Diagnostics*. 2021; 11(7):1264. <https://doi.org/10.3390/diagnostics11071264>, *IF*: 3.6
75. Proietti, I.; Skroza, N.; **Filippi, L.**; Bernardini, N.; Mambrin, A.; Tolino, E.; Rossi, G.; Marchesiello, A.; Marraffa, F.; Volpe, S.; Bagni, O.; Potenza, C. Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy. *Life* 2021, 11, 692. <https://doi.org/10.3390/life11070692>, *IF*: 3.2
76. **Filippi L**, Frantellizzi V, Chiaravalloti A, Pontico M, De Feo MS, Corica F, Montebello M, Schillaci O, De Vincentis G, Bagni O. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer. *Int J Mol Sci*. 2021 Mar 16;22(6):3036. doi: 10.3390/ijms22063036, *IF*: 5.6

77. **Filippi L**, Chiaravalloti A, Basile P, Schillaci O, Bagni O. Molecular and metabolic imaging of castration-resistant prostate cancer: state of art and future prospects. *Curr Mol Med*. 2021 Feb 10. doi: 10.2174/1566524021666210211112423. *IF*: 2.5
78. **Filippi L**, Schillaci O. New kid on the block in theranostics: Glypican-3. *Clin Transl Imaging* (2021). <https://doi.org/10.1007/s40336-021-00413-4>. *IF*: 2.1
79. Proietti I, Skroza N, **Filippi L**, Balduzzi V, Michelini S, Bagni O, Bernardini N, Maddalena P, Mambrin A, Marchesiello A, Tolino E, Volpe S, Lichtner M, Porta N, Petrozza V, Potenza C. Metastatic penile squamous cell carcinoma successfully treated with cemiplimab in an HIV patient. *Dermatol Ther*. 2021 Jan 6:e14744. doi: 10.1111/dth.14744. *IF*: 3.6
80. **Filippi L**, Spinelli GP, Chiaravalloti A, Schillaci O, Equitani F, Bagni O. Prognostic Value of 18F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223. *Biomedicines*. 2020 Nov 30;8(12):E555. doi: 10.3390/biomedicines8120555. *IF*: 4.7
81. **Filippi L**, Nervi C, Proietti I, Pirisino R, Potenza C, Martelli O, Equitani F, Bagni O. Molecular Imaging in Immuno-Oncology: Current Status and Translational Perspectives. *Expert Rev Mol Diagn*. 2020 Nov 20. doi: 10.1080/14737159.2020.1854090. *IF*: 5.1
82. **Filippi L**, Chiaravalloti A, Schillaci O, Bagni O. The potential of PSMA-targeted alpha therapy in the management of prostate cancer. *Expert Rev Anticancer Ther*. 2020;1-7. doi:10.1080/14737140.2020.1814151, *IF*: 3.3
83. Ricci M, Cimini A, Chiaravalloti A, **Filippi L**, Schillaci O. Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. *Int J Mol Sci*. 2020 Oct 11;21(20):E7481. doi: 10.3390/ijms21207481. *IF*: 5.6
84. **Filippi L**, Iannarelli A, Ambrogi C, Bagni O. Atrial metastasis from sarcomatoid renal cell carcinoma: integration between 18F-FDG PET/CT and cardiac 3D volume rendering. *Clin Nucl Med*. 2020, doi: 10.1097/RLU.0000000000003302, *IF*: 10.6
85. Cortesi E, Caponnetto S, Masi G, Urbano F, Mezi S, Gelibter A, Pelle G, **Filippi L**, Cianni R. Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer [published online ahead of print, 2020 Jun 30]. *Clin Colorectal Cancer*. 2020;S1533-0028(20)30093-1. doi:10.1016/j.clcc.2020.06.008, *IF*: 3.4
86. **Filippi L**, Fontana A, Spinelli GP, Rossi L, Bagni O. Role of 18 F-FDG PET-derived Parameters for Predicting Complete Response to Chemoradiotherapy in Squamous Cell Anal Carcinoma. *Nucl Med Commun*. 2020 Oct;41(10):1089-1094. doi: 10.1097/MNM.0000000000001260, *IF*: 3.4
87. **Filippi L**, Bagni O, Nervi C. Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer. *Expert Rev Med Devices* 2020, doi: 10.1080/17434440.2020.1796633, *IF*: 3.1
88. **Filippi L**, Bagni O, Marcellino A, Lubrano R. A rare case of a pediatric patient affected by crossed fused renal ectopia: usefulness of dual tracer 99mTc-DTPA/99mTc-DMSA scintigraphy. *The Indian Journal of Nuclear Medicine* 2020; Oct-Dec;35(4):374-376. doi: 10.4103/ijnm.IJNM_136_20. *IF*: 0.5
89. Perrone S, Ortu La Barbera E, Ottone T, Capriata M, Passucci M, **Filippi L**, Bagni O, Voso MT, Cimino G. AcutePromyelocytic Leukemia after Radium-223 exposure for prostate cancer in a chemotherapy-naive patient. *Nucl Med Mol Imaging*. 2020, doi: 10.1007/s13139-020-00652-9. *IF*: 1.3
90. **Filippi L**, Bagni O, Schillaci O. Re: "Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies" by Sicco et al. (*Cancer Biother Radiopharm* 2020;35:262-271). *Cancer Biother Radiopharm*. 2020;10.1089/cbr.2020.4014, *IF*: 3.4
91. Cimini A, Ricci M, Chiaravalloti A, **Filippi L**, Schillaci O. Theragnostic aspects and radioimmunotherapy in pediatric tumors. *Int J Mol Sci*. 2020 May 28;21(11):E3849. doi: 10.3390/ijms21113849, *IF*: 5.6
92. **Filippi L**, Pelle G, Di Costanzo GG, Tortora R, Saltarelli A, Bagni O. 18F-choline PET-aided repeated 90Y-

- radioembolization in a patient with large hepatocellular carcinoma and portal vein tumor thrombosis. *Rev Esp Med Nucl Imagen Mol* 2020, <https://doi.org/10.1016/j.remnm.2020.03.018>, *IF: 1.2*
- 93. Filippi L**, Basile P, Pirisino R, Schillaci O, Bagni O. Arrhythmogenic myocardial scar localized through the combined use of 123I-mIBG SPECT and cardiac MRI. *Rev Esp Med Nucl Imagen Mol.* 2020;39(3):177-179. doi:10.1016/j.remnm.2019.09.001, *IF: 1.2*
- 94. Filippi L**, Basile P, Schillaci O, Bagni O. The relationship between total lesion activity on 18F-choline PET-CT and clinical outcome in patients with castration resistant prostate cancer bone metastases treated with 223Radium. *Cancer Biotherapy and Radiopharmaceuticals* 2020, doi:10.1089/cbr.2019.3188, *IF: 3.4*
- 95. Proietti I, Filippi L**, Michelini S, Porta N, et al. PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach. *Clin Ter* 2020 *IF: 0.329*
- 96. Chiaravalloti A, Ricci M, Di Biagio D, Filippi L, Martorana A, Schillaci O.** The brain metabolic correlates of the main indices of neuropsychological assessment in Alzheimer's disease. *J Pers Med*, 10(2), 25, doi: 10.3390/jpm10020025, *IF: 3.4*
- 97. Filippi L**, Schillaci O, Cianni R, Bagni O. Molecular and metabolic imaging of hepatic neuroendocrine tumors following radioembolization with 90Y-microspheres. *Curr Medical Imaging* 2020;16(5):545-552. doi: 10.2174/1573405615666190114150038, *IF: 1.4*
- 98. Filippi L**, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Theranostic approaches in nuclear medicine: current status and future prospects. *Expert Rev Med Devices* 2020;17(4):331-343. doi:10.1080/17434440.2020.1741348, *IF: 3.1*
- 99. Filippi L**, Bagni O, Schillaci O. Re: Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. *Clin Nucl Med.* 2020, 2020;45(3):258–259. doi: 10.1097/RLU.0000000000002634, *IF: 10.6*
- 100. Chiaravalloti A, Filippi L**, Bagni O, Schillaci O, Czosnyka Z, Czosnyka M, De Pandis MF, Federici G, Galli M, Pompucci A, Petrella G. Cortical metabolic changes and clinical outcome in normal pressure hydrocephalus after ventriculoperitoneal shunt: our preliminary results. *Rev Esp Med Nucl Imagen Mol* 2019, doi.org/10.1016/j.remnm.2020.01.003, *IF: 1.2*
- 101. Filippi L**, Di Costanzo GG, Tortora R, Pelle G, Saltarelli A, Cianni R, Marino Marsilia G, Schillaci O, Bagni O. Prognostic value of neutrophil to lymphocyte ratio and its correlation with 18F-FDG metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Yradioembolization. *Nucl Med Commun* 2020 Jan;41(1):78-86, doi: 10.1097/MNM.0000000000001123, *IF: 1.5*
- 102. Filippi L.** Increased bone marrow 18F-choline uptake in a patient with hepatocellular carcinoma and thalassemia intermedia. *Mol Imaging Radionucl Ther* 2020;29:45-48. *IF: 0.9*
- 103. Chiaravalloti A, Filippi L**, Ricci M, Cimini A, Schillaci O. Molecular Imaging in Pediatric Brain Tumors. *Cancers* 2019, 11(12), 1853; doi.org/10.3390/cancers11121853, *IF: 5.2*
- 104. Filippi L**, Sardella B, Schillaci O, Bagni O. Mycobacterial lymphadenitis in a HIV infected patient: usefulness of 18F-FDG positron emission tomography for diagnosis and monitoring the response to treatment. *The Indian Journal of Nuclear Medicine* 2019, doi: 10.4103/ijnm.IJNM_125_19, *IF: 0.5*
- 105. Filippi L**, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. *Expert Rev Med Devices* 2019;16:341-350; doi.org/10.1080/17434440.2019.1608817, *IF: 3.1*
- 106. Filippi L**, Schillaci O, Cianni R, Bagni O. Imaging Neuroendocrine Hepatic Metastases Following 90Y-Radioembolization: Is It Time to Implement Routine Use of PET Molecular/metabolic Probes? *Cardiovasc Intervent Radiol* 2019, doi.org/10.1007/s00270-019-02186-w, *IF: 2.9*
- 107. Filippi L**, Di Costanzo GG, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O. Repeated treatment with 90Y-

- microspheres in Intrahepatic Cholangiocarcinoma Relapsed after the 1st Radioembolization. *Cancer Biotherapy and Radiopharmaceuticals* 2019, doi:10.1089/cbr.2018.2718. *IF: 3.4*
- 108.** Panebianco M, Bagni O, Cenfra N, Mecarocci S, Ortu La Barbera E, **Filippi L**, Codacci-Pisanelli G, Biondi T, Laghi A, Cimino G. Comparison of 18F FDG PET-CT AND CEPT in pretreatment staging of adults with Hodgkin's lymphoma. *Leuk Res.* 2018;76:48-52. doi: 10.1016/j.leukres.2018.11.018, *IF: 2.7*
- 109.** **Filippi L**, Chiaravalloti A, Bagni O, Schillaci O. 18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease. *Am J Nucl Med Mol Imaging.* 2018 Aug 20;8(4):268-281. *IF: 2.5*
- 110.** **Filippi L**, Schillaci O, Bagni O. 90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach. *Eur J Nucl Med Mol Imaging* 2018, doi: 10.1007/s00259-018-4115-z, *IF: 9.1*
- 111.** **Filippi L**, Di Costanzo GG, D'Agostini A, Tortora R, Cianni R, Schillaci O, Bagni O. Decrease in total lesion glycolysis and survival after 90Y-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. *Nucl Med Commun* 2018, doi: 10.1097/MNM.0000000000000879, *IF: 1.5*
- 112.** **Filippi L**, Lacanfora A, Cianni R, Schillaci O, Bagni O. 18F-FDG PET-CT Imaging of Tumor Thrombus Extending into the Right Atrium in a Patient with Cholangiocarcinoma Treated with 90Y-microspheres. *The Indian Journal of Nuclear Medicine*;2018;33:250-2. doi: 10.4103/ijnm.IJNM_50_18 *IF: 0.5*
- 113.** **Filippi L**, Schillaci O, Cianni R, Bagni O. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. *Future Oncol.* 2018 Apr;14(9):809-818. doi: 10.2217/fon-2017-0443, *IF: 3.3*
- 114.** D'Arienzo M, Pimpinella M, Capogni M, De Coste V, **Filippi L**, Spezi E, Patterson N, Mariotti F, Ferrari P, Chiamamida P, Tapner M, Fischer A, Paulus T, Pani R, Iaccarino G, D'Andrea M, Strigari L, Bagni O. Phantom validation of quantitative Y-90 PET/CT-based dosimetry in liver radioembolization. *EJNMMI Res.* 2017 Nov 28;7(1):94. doi: 10.1186/s13550-017-0341-9, *IF: 3.2*
- 115.** Kathy P. Willowson, Michael Tapner, Oreste Bagni, **Luca Filippi**, et al (The QUEST study group) A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study. *Eur J Nucl Med Mol Imaging.* 2015 Jul;42(8):1202-22. doi: 10.1007/s00259-015-3059-9, *IF: 9.1*
- 116.** **Filippi L**, Scopinaro F, Pelle G, Cianni R, Salvatori R, Schillaci O, Bagni O. Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microspheres therapy in patients with liver metastases from neuroendocrine tumors. *Eur J Nucl Med Mol Imaging.* 2016 Mar;43(3):432-40. ISSN: 1619-7070, doi: 10.1007/s00259-015-3178-3, *IF: 9.1*
- 117.** Bagni O, **Filippi L**, Pelle G, Cianni R, Schillaci O. Total lesion glycolysis and sequential 90Y-selective internal radiation therapy in breast cancer liver metastases. our preliminary results. *Cancer Biotherapy and Radiopharmaceuticals* 11/2015;30(10). ISSN: 1084-9785, DOI:10.1089/cbr.2015.1877, *IF: 3.4*
- 118.** Bagni O, **Filippi L**, Schillaci O. Incidental detection of colorectal cancer via 18F-choline PET/CT in a patient with recurrent prostate cancer: usefulness of early images. *Clin Nucl Med.* 2015 Jun;40(6):e328-30. doi:10.1097/RLU.0000000000000715, *IF: 10.6*
- 119.** Bagni O, **Filippi L**, Schillaci O.. 18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y-radioembolization: is there a role? *Eur J Nucl Med Mol Imaging.* 2015 Mar;42(3):367-9. doi: 10.1007/s00259-014-2966-5, *IF: 9.1*
- 120.** Bagni O, **Filippi L**, Schillaci O.. The role of 18FDG positron emission tomography in the follow-up of liver tumors treated with 90Yttrium radioembolization. *Am J Nucl Med Mol Imaging.* 2015 Feb 15;5(3):220-32 ISSN: 2160-8407. *IF: 2.5*
- 121.** **Filippi L**, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after 90Y radioembolization in intrahepatic cholangiocarcinoma. *Nucl Med Biol.* 2015 Jan;42(1):59-64, ISSN:0969-8051, doi: 10.1016/j.nucmedbio.2014.08.011, *IF: 3.1*

- 122. Filippi L**, Ciorra A, Sardella B, Schillaci O, Bagni O. Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors: A Case Report. *Nucl Med Mol Imaging*. 2014 Dec;48(4):321-5; doi: 10.1007/s13139-014-0292-2, *IF*: 1.3
- 123. Filippi L**, Sardella B, Ciorra A, Scopinaro F, Bagni O. Tumor Thrombus in the Renal Vein from an Adrenal Metastasis of Lung Cancer: 18FDG PET/CT Findings. *Cancer Biother Radiopharm*. 2014 Jun;29(5):189-92. doi: 10.1089/cbr.2014.1612, *IF*: 3.4
- 124.** Bagni O, **Filippi L**, Pelle G, Scopinaro F. Original Case Report F-FDG PET/CT imaging of massive portal vein tumor thrombosis from ileal adenocarcinoma. *Hellenic journal of nuclear medicine* 03/2014; 17(1):52-53. ISSN: 17905427, *IF*: 1.5
- 125.** Rossi L, Giordani E, Fontana A, Di Cristofano C, Cavallaro G, Bagni O, **Filippi L**, Bianchi L, Rinaldi G, Congedi FP, Papa A, Caruso D, Verrico M, Silecchia G, Tomao S.: An unusual case of spleen metastasis from carcinoma ex pleomorphic adenoma of the parotid gland. *World Journal of Surgical Oncology* 01/2014; 12(1):18. doi: 10.1186/1477-7819-12-18, *IF*: 3.2
- 126.** D'Arienzo M, **Filippi L**, Chiamida P, Chiacchiararelli L, Cianni R, Salvatori R, Scopinaro F, Bagni O. Absorbed dose to lesion and clinical outcome after liver radioembolization with (90)Y microspheres: a case report of PET-based dosimetry. *Ann Nucl Med*. 2013 Aug;27(7):676-80. doi: 10.1007/s12149-013-0726-4, *IF*: 2.6
- 127. Filippi L**, D'Arienzo M, Scopinaro F, Salvatori R, Bagni O. Usefulness of Dual-Time Point Imaging After Carbonated Water for the Fluorodeoxyglucose Positron Emission Imaging of Peritoneal Carcinomatosis in Colon Cancer. *Cancer Biother Radiopharm*. 2012 Feb;21(1):41-8, doi: 10.1089/cbr.2012.1179, *IF*: 3.4
- 128.** R Cianni, G Pelle, E Notarianni, A Saltarelli, P Rabuffi, O Bagni, **L Filippi**, E Cortesi. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. *Eur Radiol*. 2013 Jan;23(1):182-9. doi: 10.1007/s00330-012-2556-5, *IF*: 5.9
- 129.** Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. *J Hepatol*. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. *IF*: 25.7
- 130.** Dore F, **Filippi L**. Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw. (Reply Letter) *J Nucl Med*. 2009 Aug;50(8):1385. doi: 10.2967/jnumed.109.064634, *IF*: 9.3
- 131. Filippi L**, Uccioli L, Giurato L, Schillaci O. Diabetic foot infection: usefulness of SPECT/CT for 99mTc-HMPAO-labeled leukocyte imaging. *Journal of Nuclear Medicine* 07/2009; 50(7):1042-6. doi: 10.2967/jnumed.108.059493, *IF*: 9.3
- 132. Filippi L**, Santoni R, Nicoli P, Danieli R, Schillaci O. Intracranial tumors after radiation therapy: role of 99mTc-tetrofosmin SPECT/CT with a hybrid camera. *Cancer Biotherapy & Radiopharmaceuticals* 04/2009;24(2):229-35. doi: 10.1089/cbr.2008.0548, *IF*: 3.4
- 133.** Dore F, **Filippi L**, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. *Journal of Nuclear Medicine* 01/2009; 50(1):30-5. doi 10.2967/jnumed.107.048785, *IF*: 9.3
- 134.** Schillaci O, Spanu A, Tagliabue L, **Filippi L**, Danieli R, Palumbo B, Del Sole A, Madeddu G. SPECT/CT with a hybrid imaging system in the study of lower gastrointestinal bleeding with technetium-99m red blood cells. *The quarterly journal of nuclear medicine and molecular imaging*: 08/2009; 53(3):281-9. *IF*: 1.5
- 135. Filippi L**, Bruni C, Padovano F, Schillaci O, Simonetti G. The Value of Semi-Quantitative Analysis of 123I-FP-CIT SPECT in Evaluating Patients with Parkinson's disease. *Neuroradiology Journal*. 10/2008; 21(4):505-509. *IF*: 1.2

- 136.**Schillaci O, **Filippi L**, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. *Seminars in Nuclear Medicine* 02/2007; 37(1):34-47; doi: 10.1053/j.semnuclmed.2006.08.003, *IF: 4.9*
- 137.**Schillaci O, **Filippi L**, Danieli R, Simonetti G. Single-photon emission computed tomography/computed tomography in abdominal diseases.. *Seminars in Nuclear Medicine* 02/2007; 37(1):48-61, doi: 10.1053/j.semnuclmed.2006.07.001, *IF: 4.9*
- 138.****Filippi L**, Pulcini A, Remediani S, Masci E, Redler A, Scopinaro F, De Vincentis G. Usefulness of scintimammography with tc-99m MIBI in clinical practice. *Clinical Nuclear Medicine* 01/2007;31(12):761-3, *IF: 10.6*
- 139.****Filippi L**, Schillaci O. Usefulness of hybrid SPECT/CT in 99mTc-HMPAO-labeled leukocyte scintigraphy for bone and joint infections. *Journal of Nuclear Medicine* 01/2007; 47(12):1908-13, *IF: 9.3*
- 140.**Schillaci O, Danieli R, **Filippi L**, Romano P, Cossu E, Manni C, Simonetti G. Scintimammography with a hybrid SPECT/CT imaging system. *Anticancer research* 01/2007; 27(1B):557-62. ISSN 0250-7005, *IF: 2*
- 141.****Filippi L**, Schillaci O. SPECT/CT with a hybrid camera: a new imaging modality for the functional anatomical mapping of infections. *Expert Review of Medical Devices* 12/2006; 3(6):699-703, doi:10.1586/17434440.3.6.699, *IF: 3.1*
- 142.****Filippi L**, Biancone L, Petruzzello C, Schillaci O. Tc-99m HMPAO-labeled leukocyte scintigraphy with hybrid SPECT/CT detects perianal fistulas in Crohn disease. *Clinical Nuclear Medicine* 10/2006; 31(9):541-2, doi: 10.1097/01.rlu.0000233082.89996.3a, *IF: 10.6*
- 143.****Filippi L**, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, Schillaci O. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. *Nuclear Medicine Communications* 05/2006; 27(4):381-6, doi: 10.1097/01.mnm.0000202858.45522.df, *IF: 1.5*
- 144.****Filippi L**, Schillaci O, Santoni R, Manni C, Danieli R, Simonetti G. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin.. *Cancer Biotherapy and Radiopharmaceuticals* 03/2006; 21(1):41-8. doi: 10.1089/cbr.2006.21.41, *IF: 3.4*
- 145.**Vincentis GD, Porfiri LM, Betti M, **Filippi L**, Remediani S, Santo GD, Zaccagnino P, Felice CD, Pieracci M, Cinti MN, Bennati P, Pellegrini R, Pani R. High resolution scintimammography helps in differentiating benign from malignant findings in scintigraphic hot spots.. *Physica Medica* 02/2006; 21 Suppl 1:87-90, doi 10.1016/S1120-1797(06)80033-5, *IF: 3.4*
- 146.**Orazio Schillaci, Mariangela Pierantozzi, **Luca Filippi**, Carlo Manni, Livia Brusa, Roberta Danieli, Giorgio Bernardi, Giovanni Simonetti, Paolo Stanzione: The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson's disease. *European journal of nuclear medicine and molecular imaging* 01/2006; 32(12):1452-6. doi:10.1007/s00259-005-1922-9, *IF: 9.1*
- 147.**Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, Bernardi G, Simonetti G, Stanzione P.: 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. *Nuclear Medicine Communications* 05/2005; 26(5):421-6. doi:10.1097/00006231-200505000-00005, *IF: 1.5*
- 148.**Marignani M, Angeletti S, **Filippi L**, Danieli R, Schillaci O. Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). *International Journal of Molecular Medicine* 02/2005; 15(1):129-35, *IF: 5.4*
- 149.****Filippi L**, Santoni R, Manni C, Danieli R, Floris R, Schillaci O. Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin. *Current Medical Imaging Reviews* 12/2004; 1(1):61-66. *IF: 1.4*
- 150.**Filippi L, Valentini FB, Gossetti B, Gossetti F, De Vincentis G, Scopinaro F, Massa R. Intraoperative gamma probe detection of head and neck paragangliomas with 111In-pentetretotide: a pilot study. *Tumori* 2005; 91(2):173-6. *IF: 1.9*

Luogo e data
Roma, 02.12.2024

In fede
